Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 401–500 of 1,000
Müller, J., Ossig, C., Greiner, J. F. W., Hauser, S., Fauser, M., Widera, D., Kaltschmidt, C., Storch, A., & Kaltschmidt, B. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0078 · Cited by 46
Kim, M., Bang, J. H., Lee, J. H., Han, J., Kang, H.-W., & Jeon, W. K. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3512 · Cited by 49
Pogačnik, L., Ota, A., & Ulrih, N. P. (2020) · Cells · doi:10.3390/cells9030576 · Cited by 47
“At the cellular level, PD comes down to loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta, and the incidence of intracellular protein aggregates known as Lewy bodies [11,12].”
BackgroundBio-inspired dimensionality reduction for Parkinson’s disease (PD) classification
Pasha, A., & Latha, P. H. (2020) · Health Information Science and Systems · doi:10.1007/s13755-020-00104-w · Cited by 53
Serotonin and Melatonin Show Different Modes of Action on Aβ42 Protofibril Destabilization
Gong, Y., Zhan, C., Zou, Y. F., Qian, Z., Wei, G., & Zhang, Q. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00038 · Cited by 45
Tremor-related feature engineering for machine learning based Parkinson’s disease diagnostics
Valla, E., Nõmm, S., Medijainen, K., Taba, P., & Toomela, A. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.103551 · Cited by 45
El‐Nashar, H. A. S., Adel, M., El‐Shazly, M., Yahia, I. S., El‐Sheshtawy, H. S., Almalki, A. A., & Ibrahim, N. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200272 · Cited by 46
Huang, C., Lee, Y., Yang, Y.-C., Kuo, T.-Y., & Huang, N. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2011.12.021 · Cited by 50
“Parkinson’s disease (PD) is the second most prevalent ageelated neurodegenerative disorder (Nussbaum and Ellis, 2003).”
BackgroundLiu, C., Fei, E., Jia, N., Wang, H., Tao, R.-S., Iwata, A., Nukina, N., Zhou, J., & Wang, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700422200 · Cited by 49
Linking chronic kidney disease and Parkinson’s disease: a literature review
Meléndez-Flores, J. D., & Estrada-Bellmann, I. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00623-1 · Cited by 44
Therapies modulating insulin resistance in Parkinson’s disease: A cross talk
Sharma, T., Kaur, D., Grewal, A. K., & Singh, T. G. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135754 · Cited by 44
Cave, J. W., Wang, M., & Baker, H. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00016 · Cited by 44
Genetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu-Wai-Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 43
Non-motor symptoms in Parkinson's disease: Opening new avenues in treatment
Gupta, S., & Shukla, S. (2021) · Current Research in Behavioral Sciences · doi:10.1016/j.crbeha.2021.100049 · Cited by 48
Innate Immunity and Cell Death in Alzheimer’s Disease
Lee, S., Cho, H.-J., & Ryu, J.-H. (2021) · ASN Neuro · doi:10.1177/17590914211051908 · Cited by 45
Prajapati, R., Seong, S. H., Park, S. E., Paudel, P., Jung, H. A., & Choi, J. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-02843-6 · Cited by 44
Genetic counseling throughout the life cycle
Ciarleglio, L., Bennett, R. L., Williamson, J., Mandell, J. B., & Marks, J. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320170 · Cited by 50
Exposure to Ionizing Radiation and Risk of Dementia: A Systematic Review and Meta-Analysis
Srivastava, T., Chirikova, E., Birk, S., Xiong, F., Benzouak, T., Liu, J. Y., Villeneuve, P. J., & Zablotska, L. B. (2023) · Radiation Research · doi:10.1667/rade-22-00153.1 · Cited by 45
The Alzheimer’s Knowledge Base: A Knowledge Graph for Alzheimer Disease Research
Romano, J. D., Truong, V. Q., Kumar, R., Venkatesan, M., Graham, B. E., Hao, Y., Matsumoto, N., Li, X., Wang, Z. P., Ritchie, M. D., et al. (2024) · Journal of Medical Internet Research · doi:10.2196/46777 · Cited by 51
Network and Pathway-Based Analyses of Genes Associated with Parkinson’s Disease
Hu, Y., Pan, Z., Hu, Y. C., Zhang, L., & Wang, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9998-8 · Cited by 50
Liu, F., Dong, B., Yang, X., Yang, Y., Zhang, J., Jin, D., Ohizumi, Y., Lee, D., Xu, J., & Guo, Y. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.009 · Cited by 43
Bhattacharya, S., Xu, L., & Thompson, D. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00053 · Cited by 44
Tsoulos, I. G., Mitsi, G., Stavrakoudis, A., & Papapetropoulos, S. (2019) · Frontiers in ICT · doi:10.3389/fict.2019.00010 · Cited by 43
Kuo, Y., Nwankwo, E. I., Nussbaum, R. L., Rogers, J. T., & Maccecchini, M. L. (2019) · Europe PMC (PubMed Central) · Cited by 61
Self-citationDevi, S. A., & Chamoli, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-42667-5_7 · Cited by 47
Living with the enemy: from protein-misfolding pathologies we know, to those we want to know
Emwas, A.-H. M., Alghrably, M., Dhahri, M., Sharfalddin, A. A., Alsiary, R., Jaremko, M., Faa, G., Campagna, M., Congiu, T., Piras, M., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101391 · Cited by 44
Environmental factors in Parkinson’s disease: New insights into the molecular mechanisms
Yuan, X., Tian, Y., Liu, C., & Zhang, Z. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.12.003 · Cited by 43
Identification of Aldolase as a Target Antigen in Alzheimer’s Disease
Mor, F., Izak, M., & Cohen, I. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3439 · Cited by 43
Ariga, T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9641-0 · Cited by 45
Wang, J., He, Y., Chen, X., Huang, L., Li, J., You, Z., Huang, Q., Ren, S., He, K., Schibli, R., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01385-z · Cited by 44
Parkinson’s Disease and Risk of Fracture: A Meta-Analysis of Prospective Cohort Studies
Tan, L., Wang, Y., Zhou, L., Shi, Y., Zhang, F., Liu, L., & Nie, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094379 · Cited by 42
“It is characterized clinically by three motor symptoms including resting tremors, rigidity and bradykinesia [1,2], with an estimated prevalence of about 1% among people aged over 60 years old [3].”
BackgroundGood gene, bad gene: New APP variant may be both
Fede, G. D., Catania, M., Morbin, M., Giaccone, G., Moro, M. L., Ghidoni, R., Colombo, L., Messa, M., Cagnotto, A., Romeo, M., et al. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.004 · Cited by 46
Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Shanker, V., Groves, M., Heiman, G., Palmese, C., Saunders‐Pullman, R., Ozelius, L., Raymond, D., & Bressman, S. (2011) · Movement Disorders · doi:10.1002/mds.23746 · Cited by 40
Protective effect of curcumin in transgenic Drosophila melanogaster model of Parkinson’s disease
Siddique, Y. H., Ara, G., Jyoti, S., & Afzal, M. (2012) · Alternative Medicine Studies · doi:10.4081/ams.2012.e3 · Cited by 43
Risk of Suicide Among Patients With Parkinson Disease
Chen, Y., Sun, Y., Hu, Y., Li, C., Artaud, F., Carcaillon‐Bentata, L., Elbaz, A., & Lee, P. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.4001 · Cited by 43
Bekker, M., Abrahams, S., Loos, B., & Bardien, S. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.12.013 · Cited by 47
Pathologic Correlates of Dementia in Individuals with Lewy Body Disease
Sonnen, J. A., Postupna, N., Larson, E. B., Crane, P. K., Rose, S. E., Montine, K. S., Leverenz, J. B., & Montine, T. J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00371.x · Cited by 42
Classification-based screening of Parkinson’s disease patients through voice signal
Cordella, F., Paffi, A., & Pallotti, A. (2021) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea52024.2021.9478683 · Cited by 41
Song, J., Cho, E., Lee, H., Lee, S., Kim, S., & Kim, J. (2025) · Biosensors · doi:10.3390/bios15020102 · Cited by 46
RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer
Ahlers‐Dannen, K. E., Chakravarti, B., & Fisher, R. A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9899-9 · Cited by 48
Kim, H. D., Jeong, K. H., Jung, U. J., & Kim, S. R. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3581 · Cited by 40
Wu, Y., Pei, Y., Wang, F., Xu, D., & Cui, W. (2016) · Scientific Reports · doi:10.1038/srep31975 · Cited by 43
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson’s Disease following Oral Administration
Papapetropoulos, S., Liu, W., Duvvuri, S., Thayer, K., & Gray, D. L. (2018) · Neurodegenerative Diseases · doi:10.1159/000492498 · Cited by 41
Risk and adverse outcomes of fractures in patients with Parkinson’s disease: two nationwide studies
Huang, Y., Cherng, Y., Hsu, S. P. C., Yeh, C., Chou, Y.-C., Wu, C., Chen, T.-L., & Liao, C.-C. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3052-y · Cited by 41
Vacirca, D., Delunardo, F., Matarrese, P., Colasanti, T., Margutti, P., Siracusano, A., Pontecorvo, S., Capozzi, A., Sorice, M., Francia, A., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.013 · Cited by 46
Baldwin, C. M., & Keating, G. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00007 · Cited by 42
Modelling Alzheimer's disease: Insights fromin vivotoin vitrothree-dimensional culture platforms
Ranjan, V., Qiu, L., Tan, E., Zeng, L., & Zhang, Y. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2728 · Cited by 46
Moore, K. P., Zhu, H., Rajapakse, H. A., McGaughey, G. B., Colussi, D. J., Price, E. A., Sankaranarayanan, S., Simon, A. J., Pudvah, N. T., Hochman, J. H., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.040 · Cited by 43
Efficacy and safety of probiotics in Parkinson’s constipation: A systematic review and meta-analysis
Xie, L., Chen, D., Xinghui, Z., & Cheng, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1007654 · Cited by 40
“Parkinson’s disease (PD), which affects more than 1% of the elderly population in the world, is one of the most common neurodegenerative diseases (Nussbaum and Ellis, 2003).”
BackgroundNanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease
Arya, M. A., Kumar, M. K. M., Sabitha, M., Menon, K. N., & Nair, S. C. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.03.022 · Cited by 41
Marotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
“5 to 1 percent in people 65 to 69 years of age rising sharply to 1 to 3 percent in people over 80 years of age [173,174].”
BackgroundZheng, Y., Wang, Q., Xiao, B., Lu, Q., Wang, Y., & Wang, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039035 · Cited by 44
Motion Sensors to Assess and Monitor Medical and Surgical Management of Parkinson Disease
Lieber, B. A., Taylor, B. E. S., Appelboom, G., McKhann, G. M., & Connolly, E. S. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.03.024 · Cited by 42
“alone and approximately 1% of individuals over age 60 [1,2].”
BackgroundLack of Familial Aggregation of Parkinson Disease and Alzheimer Disease
Levy, G., Louis, E. D., Mejia-Santana, H., Côté, L., Andrews, H., Harris, J., Waters, C., Ford, B., Frucht, S., Fahn, S., et al. (2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1033 · Cited by 40
Luo, C.-S., Chi, C.-C., Fang, Y.-A., Liu, J.-C., & Lee, K.-Y. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001155 · Cited by 39
Chien, W.-L., Lee, T.-R., Hung, S.-Y., Kang, K.-H., Lee, M.-J., & Fu, W.-M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07229.x · Cited by 38
“Parkinson’s disease (PD) is the common neurodegenerative disorder, affecting more than 0.1% of the population older than 40 years of age (Nussbaum and Ellis 2003).”
BackgroundInfluentialLi, J., Liu, X.-D., Shen, L., Zeng, W.-M., & Qiu, G. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i5.27 · Cited by 47
Vanhoutte, M., Semah, F., Sillaire, A. R., Jaillard, A., Petyt, G., Kuchcinski, G., Maureille, A., Delbeuck, X., Fahmi, R., Pasquier, F., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.009 · Cited by 41
Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data
Singh, J. A., & Cleveland, J. D. (2019) · BMC Neurology · doi:10.1186/s12883-018-1234-x · Cited by 42
Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
Królicka, E., Kieć‐Kononowicz, K., & Łażewska, D. (2022) · Pharmaceuticals · doi:10.3390/ph15070847 · Cited by 40
Design and Synthesis of 2,3,5‐Substituted Imidazolidin‐4‐one Inhibitors of BACE‐1
Barrow, J. C., Rittle, K. E., Ngo, P. L., Selnick, H. G., Graham, S. L., Pitzenberger, S. M., McGaughey, G. B., Colussi, D., Lai, M., Huang, Q., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200700038 · Cited by 38
Marano, E., Briganti, F., Tortora, F., Elefante, A., Rosa, A. D., Maiuri, F., & Filla, A. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.022285 · Cited by 39
Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease
Bassil, N., Thaipisuttikul, P., & Grossberg, G. T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.493874 · Cited by 40
Chlorpyrifos-induced parkinsonian model in mice: Behavior, histopathology and biochemistry
Deveci, H. A., & Karapehlivan, M. (2017) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2017.11.002 · Cited by 41
Functions and dysfunctions of the mammalian centrosome in health, disorders, disease, and aging
Schatten, H., & Sun, Q. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1698-1 · Cited by 39
ZPD-2, a Small Compound That Inhibits α-Synuclein Amyloid Aggregation and Its Seeded Polymerization
Peña‐Díaz, S., Pujols, J., Conde-Giménez, M., Čarija, A., Dalfó, E., García, J., Navarro, S., Pinheiro, F., Santos, J., Salvatella, X., et al. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00306 · Cited by 41
Zhang, Z., Hong, R., Lin, A., Su, X., Jin, Y., Gao, Y., Peng, K., Li, Y., Zhang, T., Zhi, H., et al. (2021) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-021-00959-4 · Cited by 39
Adrissi, J., & Fleisher, J. E. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01212-8 · Cited by 38
Li, D., Huang, L., Zhang, C.-P., Li, Q., & Wang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.890509 · Cited by 42
“100,000 people per year, the median age of the onset is 60 years, and the progression time from diagnosis to death is almost 15 years (Nussbaum and Ellis, 2003; Tysnes and Storstein, 2017).”
BackgroundAntiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson’s Disease
Wei, Y. J., Palumbo, F. B., Simoni, J. M., Shulman, L. M., Stuart, B., Beardsley, R. S., & Brown, C. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.001 · Cited by 38
Fujimoto, E., Stevenson, T. J., Chien, C.-B., & Bonkowsky, J. L. (2011) · Developmental Biology · doi:10.1016/j.ydbio.2011.01.023 · Cited by 37
Treadmill Training for Individuals With Parkinson Disease
Earhart, G. M., & Williams, A. J. (2012) · Physical Therapy · doi:10.2522/ptj.20110471 · Cited by 41
Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson’s disease
Wei, X., Yan, R., Chen, Z., Weng, R., Liu, X., Gao, H., Xu, X., Kang, Z., Liu, Z., Guo, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep33762 · Cited by 39
Hartmann, J., Erb, C., Ebert, U., Baumann, K., Popp, A., König, G., & Klein, J. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.02.038 · Cited by 41
Microglia-driven inflammation induces progressive tauopathies and synucleinopathies
Lee, S. H., Bae, E.-J., Park, S. J., & Lee, S. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01450-z · Cited by 39
Xu, J., Kang, J., Sun, X., Cao, X., Kasimu, R., Lee, D., Ren, Q., Shen, L., Ohizumi, Y., & Guo, Y. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00815 · Cited by 38
Family experiences as a caregiver for patients with Parkinson's disease: a qualitative study
Dekawaty, A., Malini, H., & Fernandes, F. (2019) · Journal of research in nursing · doi:10.1177/1744987118816361 · Cited by 37
“In contrast, Alzheimer’s disease is a neurological disorder characterised by an irreversible loss of neurons in the cortex and hippocampus, resulting in impairment of memory, judgement, orientation to surroundings, and language and decision making (Nussbaum and Ellis, 2003).”
BackgroundBranscome, H., Paul, S., Khatkar, P., Kim, Y., Barclay, R. A., Pinto, D. O., Yin, D., Zhou, W., Liotta, L. A., El‐Hage, N., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09865-y · Cited by 37
He, M., Fan, M., Peng, Z., & Wang, G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113546 · Cited by 43
Xiao, Z., Huang, C., Wu, J., Sun, L., Hao, W., Leung, L. K., & Huang, J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.023 · Cited by 38
Li, J., Han, Q., Wang, X., Yu, N., Yang, L., Yang, R., & Wang, C. (2014) · Small · doi:10.1002/smll.201401121 · Cited by 40
The role of magnetic resonance imaging in the diagnosis of Parkinson's disease: a review
Al‐Radaideh, A., & Rababah, E. M. (2016) · Clinical Imaging · doi:10.1016/j.clinimag.2016.05.006 · Cited by 46
Nural, H. F., He, P., Beach, T. G., Sue, L. I., Xia, W., & Shen, Y. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-23 · Cited by 37
“Patients with autosomal recessive juvenile parkinsonism, a relatively rare syndrome that shares many of the features of parkinsonism but without the presence of Lewy bodies or Lewy neurites at autopsy [28,29], were excluded from this study.”
BackgroundPolymorphisms of pro-inflammatory genes and Alzheimer's disease risk: A pharmacogenomic approach
Candore, G., Balistreri, C. R., Grimaldi, M. P., Listì, F., Vasto, S., Chiappelli, M., Licastro, F., Colonna‐Romano, G., Lio, D., & Caruso, C. (2006) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.013 · Cited by 41
The molecular mechanism of aging and the role in neurodegenerative diseases
Zhao, J., Han, Z.-J., Ding, L., Wang, P., He, X., & Li, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24751 · Cited by 43
“Its hallmarks include reduced synaptic connection and gradual, cumulative neuronal death are [101].”
BackgroundGenetic of Alzheimer's Disease: A Narrative Review Article.
Khanahmadi, M., Farhud, D. D., & Malmir, M. (2015) · PubMed Central · Cited by 56
Karadsheh, M. S., Weaver, M. J., Rodriguez, K., Harris, M. B., Zurakowski, D., & Lucas, R. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-015-4262-5 · Cited by 37
“Although the disease affects 1% of people older than 65 years [17], data are limited and conflicting whether Parkinson’s disease is a distinct prognostic factor when treating femoral neck fractures regarding mortality, rate of reoperation, rate of dislocation, and failure rate of internal fixation.”
BackgroundA molecular rotor-based turn-on sensor probe for amyloid fibrils in the extreme near-infrared region
Mudliar, N. H., & Singh, P. K. (2019) · Chemical Communications · doi:10.1039/c9cc01262a · Cited by 36
Costa, A. C., Madsen, H., & Brown, J. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-45129-8 · Cited by 38
Epigenetic inactivation of the autophagy–lysosomal system in appendix in Parkinson’s disease
Gordevičius, J., Li, P., Marshall, L. L., Killinger, B. A., Lang, S., Ensink, E., Kuhn, N. C., Cui, W., Maroof, N., Lauria, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25474-x · Cited by 38
Wei, Y. J., Palumbo, F. B., Simoni, J. M., Shulman, L. M., Stuart, B., Beardsley, R. S., & Brown, C. H. (2014) · Value in Health · doi:10.1016/j.jval.2013.12.003 · Cited by 40
“[1] Nussbaum RL, Ellis CE.”
BackgroundExon Arrays Reveal Alternative Splicing Aberrations in Parkinson’s Disease Leukocytes
Soreq, L., Bergman, H., Israel, Z. H., & Soreq, H. (2011) · Neurodegenerative Diseases · doi:10.1159/000332598 · Cited by 40
Prevalence of neurogenetic disorders in the North of England
Bargiela, D., Yu‐Wai‐Man, P., Keogh, M. J., Horváth, R., & Chinnery, P. F. (2015) · Neurology · doi:10.1212/wnl.0000000000001995 · Cited by 39
When Language Breaks Down: Analysing Discourse in Clinical Contexts
Asp, E. D., & de Villiers, J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511845352 · Cited by 50
Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
Wang, Z., Wang, Q., Li, S., Li, X.-J., Yang, W., & He, D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1065183 · Cited by 35
“They are featured by selective neuronal vulnerability in specific brain regions and intracellular or extracellular deposits of abnormal proteins in or between neurons and other cells (Wong et al., 2002; Nussbaum and Ellis, 2003; Selkoe, 2003; Ross and Pickart, 2004).”
BackgroundDeep Learning for Detecting Freezing of Gait Episodes in Parkinson’s Disease Based on Accelerometers
Camps, J., Samà, A., Martín, M., Rodríguez-Martín, D., Pérez‐López, C., Alcaine, S., Mestre, B., Prats, A., Crespo, M. C., Cabestany, J., et al. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-59147-6_30 · Cited by 41
“Parkinson’s disease (PD), with a prevalence of approximately 1% among people of age above 65, is the second most common neurodegenerative disorder [15,16,23,26].”
BackgroundAnalysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease
Fernández, M. V., Kim, J. H., Budde, J., Black, K., Medvedeva, A., Saef, B. A., Deming, Y. K., Del‐Aguila, J. L., Ibáñez, L., Dube, U., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007045 · Cited by 38
A microfiber scaffold-based 3D in vitro human neuronal culture model of Alzheimer's disease
Ranjan, V., Qiu, L., Lee, J. W. L., Chen, X., Jang, S. E., Chai, C., Lim, K., Tan, E., Zhang, Y., Huang, W., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00833h · Cited by 38
Life Satisfaction and Adaptation in Persons with Parkinson’s Disease—A Qualitative Study
Rosengren, L., Forsberg, A., Brogårdh, C. B., & Lexell, J. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063308 · Cited by 35
Buck, S. A., Miranda, B. R. D., Logan, R. W., Fish, K. N., Greenamyre, J. T., & Freyberg, Z. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2770-20.2021 · Cited by 35
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.